key: cord-0690540-mbob5kgm
authors: Simpson‐Poirier, Kevin; Harnois, Michaël; Olney, Harold J.; Sirhan, Shireen; Gratton, Michel‐Olivier; Assouline, Sarit; Laneuville, Pierre; Delage, Robert; Mollica, Luigina; Busque, Lambert; Szuber, Natasha
title: Risk of infection in MPN patients in the era of Covid‐19: A prospective multicenter study of 257 patients from the CML‐MPN Quebec Research Group
date: 2021-03-26
journal: Am J Hematol
DOI: 10.1002/ajh.26159
sha: d29ba2aa90e1e4a58c86ec490f5fef94e51b53e4
doc_id: 690540
cord_uid: mbob5kgm

nan

were as follows: urinary tract (11%), ears nose throat (ENT) (9%), otherincluding dental, vaginal, and epididymal (7%), cutaneous (6%), herpes zoster (5%), bronchitis (4%), pneumonia (3%), gastrointestinal (GI) (2%), and Covid-19 (1%). Infection types were proportional across MPN subtypes with the exception of a trend towards higher rates of zoster infection in the MF sub-group (14% vs. 3% PV and 4% ET; p = .08). Antibiotic, antiviral, and antifungal prophylaxis had been received by 3 (1%), 3 (1%), and 1 (<1%) patient, respectively, with the majority consisting of MF patients. Vaccinations for influenza, herpes zoster, and pneumococcal pneumonia had been reported in 115 (45%), 16 (6%), and 19 (7%) patients, respectively, with no bias in MPN type.

Clinical parameters of MPN patients stratified according to occurrence of infectious complications are detailed in Table S1 . No appreciable differences were detected on the basis of age (>65 years old vs. younger; p = .4), MPN subtype (p = .6), driver mutation (p = .9), or concurrent aspirin therapy (p = .3). Analysis by gender disclosed a higher frequency of infections in females versus males (38% vs. 26%; p = .04). From a treatment standpoint, most of the patients treated with ruxolitinib in the past 12 months presented at least one infectious event (n = 18; 56%), while events were reported in 39%, 30%, and 13% of those having received multiple/combination therapies, hydroxyurea, and anagrelide, respectively. As 18 patients (8%) had received either multiple agents or combinations thereof, specification of any RUX use in the past 12 months disclosed a significant association with infectious events (p = .001), while none were observed with hydroxyurea use (p = .2). Of note, none of the four patients treated with interferon and, conversely, both patients treated with busulfan, This multicenter prospective, patient-reported study of infection outcomes in MPN confirms clinically relevant rates of infection in all MPN subtypes, though somewhat lower than those previously described (33% vs. previously reported 45-50%). 1,3 Though limited by factors including potential recall and regional biases, as well as logistics beyond the scope of this report, such as disease and therapy duration, co-morbidities, complete drug history, or infection grade, the current study critically represents a large dataset derived from an "all-comers" highly inclusive MPN registry, circumventing the bias towards reporting solely severe infections/hospitalizations, and addresses fundamental questions about the prevalent phenomenon of infections in MPN from a practical, real-world standpoint.

Interestingly, our data did not disclose a significant association between infection risk and advanced age, a finding which concurs with some, 1 though not other reports, 2 suggesting an uncertain role for age as a substantive, isolated risk factor for infections in MPN.

study is challenging to interpret, but may be due to gender differences in adverse event reporting, known to occur in some patient-reported study settings, and possibly disproportionate representation of UTI in the range of infections. Importantly, in contrast with another similarly-designed study, 1 while more MF patients experienced infectious events compared to their PV/ET counterparts, this did not meet statistical significance, suggesting that in our cohorts, other variables (e.g., disease duration, risk category, or perhaps newly-instituted public health pandemic restrictions and practices) may have more markedly influenced outcomes. Of note, the fact that data collection occurred during, and pertained to (in part), the period affected by the global Covid-19 pandemic, greater caution may have been exercised by these patients, potentially affecting infection endpoints. As certain of our observations challenge data from previous reports 1 (e.g., lower rates of infection, lack of association with MPN sub-type), highlighted by the fact that few patients in our cohort contracted Covid-19 (much less than would be expected given provincial infection rates and the median age of our cohort), the far-reaching impact of the pandemic and asso- Bronchitis; n (%) 11 (4) 6 (6) 5 (4) 0 (0) .1

Pneumonia; n (%) 7 (3) 2 (2) 5 (4) 0 (0) .2

Gastrointestinal; n (%) 6 (2) 1 (1) 5 (4) 0 (0) .1

Skin; n (%) 16 (6) 6 (6) 9 (7) 1 (3) .6

Urinary tract; n (%) 27 (11) 9 (9) 14 (11) 4 (11) .9

Herpes zoster; n (%) 13 (5) 3 (3) 5 (4) 5 (14)

.08

Covid-19; n (%) 2 (1)

Other c ; n (%) 18 (7) 9 (9) 7 (6) 2 (5) .5

Antibiotic; n (%) 

Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a National Population-Based Cohort Study

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: a multicenter study on 446 patients